AAL 993 structure
|
Common Name | AAL 993 | ||
---|---|---|---|---|
CAS Number | 269390-77-4 | Molecular Weight | 371.356 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 441.3±45.0 °C at 760 mmHg | |
Molecular Formula | C20H16F3N3O | Melting Point | N/A | |
MSDS | N/A | Flash Point | 220.7±28.7 °C |
Use of AAL 993IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties[1]. |
Name | 2-[(4-Pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzami de |
---|---|
Synonym | More Synonyms |
Description | IC50s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties[1]. |
---|---|
Related Catalog | |
Target |
VEGFR1:130 nM (IC50) VEGFR2:23 nM (IC50) VEGFR3:18 nM (IC50) |
In Vitro | AAL993 suppresses HIF-1α expression through ERK inhibition without affecting Akt phosphorylation[2]. |
In Vivo | AAL993 (compound 5) potently inhibits VEGF-induced angiogenesis in an implant model, with an ED50 value of 7 mg/kg[1]. In B16 melanoma xenograft model, AAL993 (24-100 mg/kg; p.o.; daily; for 14days) inhibits both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases[1]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 441.3±45.0 °C at 760 mmHg |
Molecular Formula | C20H16F3N3O |
Molecular Weight | 371.356 |
Flash Point | 220.7±28.7 °C |
Exact Mass | 371.124542 |
PSA | 57.51000 |
LogP | 4.51 |
Vapour Pressure | 0.0±1.1 mmHg at 25°C |
Index of Refraction | 1.631 |
2-[(pyridin-4-ylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
2-((4-pyridyl)methyl)amino-N-(3-(trifluoromethyl)phenyl)benzamide |
2-[(4-Pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
Benzamide, 2-[(4-pyridinylmethyl)amino]-N-[3-(trifluoromethyl)phenyl]- |
AAL993 |